P.L. 112-144, The Food and Drug Administration Safety and Innovation Act (12 wiki edits: view article ↓)

  • This item is from the 112th Congress (2011-2012) and is no longer current. Comments, voting, and wiki editing have been disabled, and the cost/savings estimate has been frozen.

S. 3187 would amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and medical devices, to establish user-fee programs for generic drugs and biosimilars.

(

From the Blog

WashingtonWatch.com Digest – July 16, 2012

This is the WashingtonWatch.com email newsletter for the week of July 16, 2012. Subscribe (free!) here. email newsletter | tell a friend | wiki | about | home | log in On the Blog: FY 2013 Spending Bills Most of the bills to fund the government in fisc...

Visitor Comments Comments Feed for This Bill

There are currently no comments for this bill

RSS Feeds for This Bill

Keep yourself updated on user contributions and debates about this bill! (Learn more about RSS.)